Tarsus制药公司的首席执行官出售了9%的股份, 但分析师仍然建议买下股票。 Tarsus Pharmaceuticals' CEO sold 9% of his shares, but analysts still recommend buying the stock.

Tarsus制药公司是一家以眼科保健为重点的生物制药公司,其首席执行官Bobak R. Azamian出售了相当大一部分股份,其所有权减少了大约9%。 Tarsus Pharmaceuticals, a biopharmaceutical company focused on eye care, saw its CEO, Bobak R. Azamian, sell a significant portion of his shares, reducing his ownership by about 9%. 公司的主要产品XDEMVY 治疗各种病症,如脑膜炎。 The company's lead product, XDEMVY, treats conditions like blepharitis. 尽管最近有内幕销售,分析师对股票的“Buy”评级为63.67美元,目标价格为63.67美元。 Despite recent insider sales, analysts have a "Buy" rating on the stock with a target price of $63.67. Tarsus市值上限为19.2亿美元,主要由机构投资者拥有。 Tarsus has a market cap of $1.92 billion and is largely owned by institutional investors.